Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Preferred Stock and Changes in Stockholders??? (Deficit) Equity (Unaudited)

v3.24.2
Condensed Consolidated Statements of Preferred Stock and Changes in Stockholders’ (Deficit) Equity (Unaudited) - USD ($)
$ in Thousands
Total
Series C Preferred Stock
Series C Preferred Stock
AlmataBio Transaction
Series C Preferred Stock
Private Placement
Series D Preferred Stock
Series D Preferred Stock
Private Placement
Series E Preferred Stock
Series E Preferred Stock
Private Placement
Common stock
Additional paid-in capital
Accumulated deficit
Balance at the beginning (in shares) at Dec. 31, 2022                 39,294    
Balance at the beginning at Dec. 31, 2022 $ (10,915)               $ 0 [1] $ 292,909 [1] $ (303,824)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Issuance of shares of common stock and warrants in underwritten public offering, net (in shares)                 15,709    
Issuance of shares of common stock and warrants in underwritten public offering, net 13,748                 13,748 [1]  
Stock-based compensation 855                 855 [1]  
Net loss (9,955)                   (9,955)
Balance at the end (in shares) at Mar. 31, 2023                 55,003    
Balance at the end at Mar. 31, 2023 $ (6,267)               $ 0 [1] 307,512 [1] (313,779)
Balance at the beginning (in shares) at Dec. 31, 2023 0 0     0   0        
Balance at the beginning at Dec. 31, 2023 $ 0 $ 0     $ 0   $ 0        
Increase (Decrease) in Temporary Equity [Roll Forward]                      
Issuance of stock     2,412 19,946   1   1      
Issuance of Series C Preferred Stock pursuant to Almata Transaction     $ 11,457                
Balance at the end at Mar. 31, 2024 $ 11,457 $ 11,457     $ 0   $ 0        
Balance at the end (in shares) at Mar. 31, 2024 22,360 22,358     1   1        
Balance at the beginning (in shares) at Dec. 31, 2023 801,746               801,746    
Balance at the beginning at Dec. 31, 2023 $ 7,304               $ 1 342,437 (335,134)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Impact of reverse split fractional share round-up (in shares)                 60,779    
Issuance of common stock and preferred stock as part of Almata Transaction (in shares)                 171,605    
Issuance of common stock pursuant to Almata Transaction 815                 815  
Stock-based compensation 629                 629  
Net loss $ (121,290)                   (121,290)
Balance at the end (in shares) at Mar. 31, 2024 1,034,130               1,034,130    
Balance at the end at Mar. 31, 2024 $ (112,542)               $ 1 $ 343,881 $ (456,424)
[1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-240 reverse stock split effected on December 28, 2023. See Note 1 for details.